17-α Hydroxyprogesterone Nanoemulsifying Preconcentrate-Loaded Vaginal Tablet: A Novel Non-Invasive Approach for the Prevention of Preterm Birth

Preterm birth (PTB) is a major cause of infant mortality in the United States and around the globe. Makena(®)—once-a-week intramuscular injection of 17-α Hydroxyprogesterone caproate (17P)—is the only FDA approved treatment for the prevention of PTB. Invasive delivery of 17P requires hospitalization...

Descripción completa

Detalles Bibliográficos
Autores principales: Patki, Manali, Giusto, Kiersten, Gorasiya, Samir, Reznik, Sandra E., Patel, Ketan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680947/
https://www.ncbi.nlm.nih.gov/pubmed/31337153
http://dx.doi.org/10.3390/pharmaceutics11070335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680947/
https://www.ncbi.nlm.nih.gov/pubmed/31337153
http://dx.doi.org/10.3390/pharmaceutics11070335

Ejemplares similares